K. Bańkowski

发表

Synthesis, physicochemical and biological evaluation of technetium-99m labeled lapatinib as a novel potential tumor imaging agent of Her-2 positive breast cancer.

L. Królicki, E. Gniazdowska, P. Koźmiński, 2014, European journal of medicinal chemistry.

Characterization of a novel, linear radioiodinated vasopressin antagonist: an excellent radioligand for vasopressin V1a receptors.

Y. Arsenijévic, E. Tribollet, J. Dreifuss, 1995, Neuroendocrinology.

Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors.

S. Stoev, M. Manning, C. Barberis, 1995, Advances in experimental medicine and biology.

99mTc-labeled vasopressin peptide as a radiopharmaceutical for small-cell lung cancer (SCLC) diagnosis.

E. Gniazdowska, P. Koźmiński, Paweł Ochman, 2014, Journal of medicinal chemistry.

Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.

S. Stoev, M. Manning, A. Misicka, 1992, Journal of medicinal chemistry.

N‐terminal guanidinylation of the cyclic 1,4‐ureido‐deltorphin analogues: the synthesis, receptor binding studies, and resistance to proteolytic digestion

Z. Szewczuk, P. Stefanowicz, A. Lesniak, 2015, Journal of Peptide Science.

Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.

M. Manning, A. Olma, W. Sawyer, 1989, Journal of medicinal chemistry.

Selective Agonists and Antagonists of Vasopressin

M. Manning, W. Sawyer, K. Bańkowski, 1987 .

Design of potent antagonists of the vasopressor response to arginine-vasopressin.

M. Manning, W. Sawyer, K. Bańkowski, 1978, Journal of medicinal chemistry.

Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

G. Guillon, S. Stoev, M. Manning, 2012, Journal of neuroendocrinology.

The synthesis of indolo[2,3-b]quinoline derivatives with a guanidine group: highly selective cytotoxic agents.

D. Andes, J. Wietrzyk, M. Świtalska, 2015, European journal of medicinal chemistry.

Antinociceptive effect of d-Lys^2, Dab^4 N-(ureidoethyl)amide, a new cyclic 1-4 dermorphin/deltorphin analog

M. Kowalczyk, J. Kocik, B. Antkowiak, 2014, Pharmacological reports : PR.

An exploration of the effects of L‐ and D‐tetrahydroisoquinoline‐3‐carboxylic acid substitutions at positions 2,3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin

S. Stoev, M. Manning, W. Kliś, 1995, Journal of peptide science : an official publication of the European Peptide Society.

C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.

M. Manning, A. Misicka, A. Olma, 1987, Journal of medicinal chemistry.

Design and synthesis of potent in vivo antagonists of oxytocin.

M. Manning, W. Sawyer, J. Seto, 2009, International journal of peptide and protein research.

125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand.

E. Tribollet, J. Dreifuss, M. Manning, 1988, European journal of pharmacology.

Potent V2 vasopressin antagonists with structural changes at their C-terminals

S. Stoev, M. Manning, A. Misicka, 1988, Peptides.

The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin.

M. Manning, A. Turan, W. Sawyer, 1980, Endocrinology.

Physicochemical characteristics of sunitinib malate and its process-related impurities.

A. Kutner, K. Woźniak, Katarzyna Sidoryk, 2013, Journal of pharmaceutical sciences.

Novel approach to the design of synthetic radioiodinated linear V1A receptor antagonists of vasopressin.

M. Manning, C. Barberis, J. Elands, 2009, International journal of peptide and protein research.

2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists.

M. Manning, A. Misicka, W. Sawyer, 1989, Journal of medicinal chemistry.

Synthesis, biological activity and resistance to proteolytic digestion of new cyclic dermorphin/deltorphin analogues.

Z. Szewczuk, P. Stefanowicz, E. Szymanek, 2013, European journal of medicinal chemistry.

Physicochemical characterization of ezetimibe and its impurities

P. Cmoch, Katarzyna Sidoryk, W. Maruszak, 2011 .

A Novel Approach to the Design and Synthesis of Radio-Iodinated Linear Antagonists of Vasopressin and Oxytocin,

M. Manning, S. Audigier, C. Barberis, 1992 .